Targeting mTOR for cancer therapy
By H. Hua, Qingbin Kong, Hongying Zhang, Jiao Wang, T. Luo, Yangfu Jiang. Journal of Hematology & Oncology, 2019
757 citations recorded by the source corpus.
Mechanistic target of rapamycin (mTOR) is a protein kinase regulating cell growth, survival, metabolism, and immunity. mTOR is usually assembled into several complexes such as mTOR complex 1/2 (mTORC1/2). In cooperation with raptor, rictor, LST8, and mSin1, key components in mTORC1 or mTORC2, mTOR catalyzes the phosphorylation of multiple targets such as ribosomal protein S6 kinase β-1 (S6K1), eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1), Akt, protein kinase C (PKC), and type-I insulin-like growth factor receptor (IGF-IR), thereby regulating protein synthesis, nutrients metabolism, growth factor signaling, cell growth, and migration. Activation of mTOR promotes tumor growth and metastasis. Many mTOR inhibitors have been developed to treat cancer. While some of the mTOR inhibitors have been approved to treat human cancer, more mTOR inhibitors are being evaluated in clinical trials. Here, we update recent advances in exploring mTOR signaling and the development of mTOR inhibitors for cancer therapy. In addition, we discuss the mechanisms underlying the resistance to mTOR inhibitors in cancer cells.
Subfields: Molecular Biology
View Paper: https://www.semanticscholar.org/paper/4b23e3258297b184c83ead1c2a7e0964b29956cc
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Molecular Biology
- Rajiv K. Tonk
- Vivek Panwar
- Manini Bhatt
- Shinjinee Sengupta
- Manoj Garg
- Aishwarya Singh
- A. Raza
- Deepak Kumar
Citations in the corpus
- Multifaceted role of mTOR (mammalian target of rapamycin) signaling pathway in human health and disease (2023, background): “5,9 Therefore, mTOR represents an important and promising target for therapeutic intervention against human malignancies.”